Zion Market Research has published a new report titled “Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”. According to the report, global Myocardial Infarction Treatment Market was valued at approximately USD 1206.5 million in 2016 and is expected to generate revenue of around USD 1726.3 million by end of 2022, growing at a CAGR of around 6.1% between 2017 and 2022.
Browse the full report at https://www.zionmarketresearch.com/report/myocardial-infarction-treatment-market
Myocardial infarction or heart attack is caused due to blockage in the supply of oxygen-rich blood to heart muscles, resulting in permanent heart muscle injury and death of cells. The blockage is due to atherosclerosis, a process in which the plaque (fatty patches) is formed on the inside wall of the coronary artery or one of its smaller branches. If the plaque is ruptured, the blood clot is formed inside the artery blocking the blood flow. People with risk factors such as smoking, dyslipidemia, diabetes are more prone to myocardial infarction.
Global Myocardial Infarction Treatment market is primarily driven by growing incidences of cardiovascular diseases and changes in lifestyle. Other major driving factors are risk factors such as obesity, hypertension, diabetes, reduced physical activity, and rise in a number of smokers. As per WHO, the risk of myocardial infarction is increased in smokers than non-smokers. However, the high price of drug research and development and stringent regulatory policies coupled with high cost of clinical trials may pose the challenge to myocardial infarction treatment market. Nevertheless, increase in acceptance of newer treatment technologies by emerging nations and technology breakthroughs are expected to act new avenues for myocardial infarction treatment market in near future.
The Myocardial Infarction Treatment market is segmented on the basis of different product type including Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics. Analgesics and antiplatelet agent segments are expected to grow at the fastest rate during the forecast period.
The myocardial infarction treatment market is segmented based on distribution channel into Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores. Based on geography, the myocardial infarction treatment market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.
North America is expected to remain the dominant region over the forecast period. Increased incidences of cardiovascular diseases and rising aging population expected to boost the market in this region. Expiration of blockbuster drugs in the European market will impact global market share of myocardial infarction treatment market. Also, Asia Pacific market is projected to grow during the forecast period. Latin America and Middle East & Africa regions are also expected to experience noticeable growth in the years to come owing to the high incidence rate of cardiovascular diseases.
Some of the key players in Myocardial Infarction Treatment market include Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, AstraZeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.